Last reviewed · How we verify

NCT05915910

Prospective Collection of Biospecimen in Pediatric Patients and Adult Guardians Diagnosed With Glycogen Storage Disease Type 1B (GSD1b)

Terminated Last updated 19 April 2024
What this trial tests

trial testing Specimen Donation in Glycogen Storage Disease Type IB in 6 participants. Terminated before completion.

Timeline
27 April 2023
Primary endpoint
13 March 2024
13 March 2024

Quick facts

Lead sponsorSanguine Biosciences
StatusTerminated
Study typeOBSERVATIONAL
Enrollment6
Start date27 April 2023
Primary completion13 March 2024
Estimated completion13 March 2024
Sites1 location across United States

Drugs / interventions tested

Conditions studied

Sponsor

Sanguine Biosciences

Who can join

Adults 4 to 85, any sex, with Glycogen Storage Disease Type IB. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The primary objective of this study is to collect whole blood from patients diagnosed with Glycogen storage disease type 1B, which will be used to support the investigation of potential therapies that address the genetic basis of this disease.

Publications & conference data

No peer-reviewed publications indexed yet for this trial.

Verify or expand the search:

Other trials of Specimen Donation

Trials testing the same drug.

Other Sanguine Biosciences trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05915910.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing